Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RTX-200
- Development stage
- Preclinical
- Lead developer
- Resonant Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
RTX-200 is a preclinical antibody-based therapeutic being developed by Resonant Therapeutics for the treatment of lung and ovarian cancers. It was identified using Resonant's proprietary discovery platform, which focuses on identifying novel targets within the tumor microenvironment by analyzing tumor-cell interactions. RTX-200 specifically targets an undisclosed immune regulator to modulate the immune response against tumor cells. While the company's pipeline indicates that its antibodies are being developed in various formats—including naked antibodies, antibody-drug conjugates (ADCs), and bispecifics—RTX-200 is currently categorized as an antibody in the preclinical stage of development.
Beyond the preview
Go deeper on RTX-200.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RTX-200.